<DOC>
	<DOCNO>NCT02358395</DOCNO>
	<brief_summary>This open-label , multicenter , phase 1 study BBI608 combination Sorafenib . This study population adult Japanese patient advance hepatocellular carcinoma Sorafenib combination therapy .</brief_summary>
	<brief_title>A Study BBI608 Administrated With Sorafenib Adult Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically diagnose image hepatocellular carcinoma , indicate ) ) . 1 . Radiofrequency ablation therapy ( RFA ) 2 . Local therapy [ percutaneous transhepatic ethanol injection therapy ( PEIT ) , Microwave coagulation therapy ( MCT ) ] 3 . Transcatheter arterial embolization ( TAE ) 4 . Transcatheter arterial chemoembolization ( TACE ) ≥ 20 year age . Not treatment systemic chemotherapy . Signed write informed consent must obtain document . Life expectancy ≥ 3 month . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Must Child Pugh Class A. Hemoglobin ≥ 8.5 mg/dl . Absolute neutrophil count ≥ 1.5 x 10^9 /L . Platelets ≥ 75 x 10^9/L . Creatinine ≤ 1.5 x ULN . Total Bilirubin ≤ 3.0 mg/dl . Aspartate Aminotransferase ( AST ) Alanine transaminase ( ALT ) ≤ 5.0 x upper limit normal ( ULN ) . Females childbearing potential must negative serum pregnancy test . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last BBI608 dose . Have ) ) treatment le 28 day prior begin enrolment . 1 . Radiation therapy 2 . Hormone therapy 3 . Immune therapy 4 . Hyperthermia 5 . Surgical procedure 6 . Local therapy ( RFA , PEIT , MCT ) 7 . TAE 8 . TACE 9. anti tumour treatment Have brain metastasis symptom require treatment . Have coinstantaneous active multiple cancer . Have carcinomatous pleural effusion , ascites , cardiac effusion require treatment . Esophageal varix require treatment . Patient pregnancy possibility pregnancy , plan breastfeed end BBI608 administration 30days . Crohns disease , ulcerative colitis , historical surgery extensively small intestine resection . Unable unwilling swallow BBI608 capsule Sorafenib tablet . Uncontrolled intercurrent illness ( Grade 3active infection , serious respiratory disease ) . HIV infection . Abnormal ECGs clinically significant within 28 day enrolment . Patients New York Heart Association ( NYHA ) functional class III , IV , unstable angina . Patients newly express angina within three month enrolment . Have myocardial infarction within six month enrolment . Administrating antiarrhythmic drug . Have receive investigational product postmarketing investigational product within 4 week first dose BBI608 . Prior treatment BBI608 . Hypersensitivity Sorafenib component Sorafenib . Ineligible participation study opinion Investigators .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>